Discrimination of SARS-Cov 2 and arboviruses (DENV, ZIKV and CHIKV) clinical features using machine learning techniques: a fast and inexpensive clinical screening for countries simultaneously affected by both diseases

João Daniel S. Castro^{a, b*}

joaodasc@gmail.com

^a Universidade do Estado da Bahia, Departamento de Ciências Exatas e da Terra, Programa de Pós-Graduação em Química Aplicada, Salvador, BA, Brazil,

^b Secretária da Educação do Estado da Bahia, Centro Administrativo da Bahia - CAB, Salvador, BA, Brazil

Abstract

SARS-Cov-2 (Covid-19) has spread rapidly throughout the world, and especially in tropical countries already affected by outbreaks of arboviruses, such as Dengue, Zika and Chikungunya, and may lead these locations to a collapse of health systems. Thus, the present work aims to develop a methodology using a machine learning algorithm (Support Vector Machine) for the prediction and discrimination of patients affected by Covid-19 and arboviruses (DENV, ZIKV and CHIKV). Clinical data from 204 patients with both Covid-19 and arboviruses obtained from 23 scientific articles and 1 dataset were used. The developed model was able to predict 93.1% of Covid-19 cases and 82.1% of arbovirus cases, with an accuracy of 89.1% and Area under Roc Curve of 95.6%, proving to be effective in prediction and possible screening of these patients, especially those affected by Covid-19, allowing early isolation.

Keywords: Coronavirus; Covid-19; Arbovirus; Machine Learning; Clinical Features; Dengue; Zika; Chikungunya

Introduction

- 1 In December 2019, a series of pneumonia cases of unknown cause emerged among
- 2 visitors to a wet market in the city of Wuhan, Hubei (China). Genetic sequencing of
- 3 samples from the respiratory tract of these patients identified a new type of Coronavirus,

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

called (2019-nCoV) [1], which since the outbreak, has affected more than 1 million people and totals 60,000 deaths worldwide [2,3].

Covid-19 produces a systemic respiratory disease that can progress to severe pneumonia in approximately 16% of cases [4]. Sepsis is the most frequent complication, followed by respiratory failure, acute respiratory distress (ARDS), heart failure and septic shock [5].

Concomitantly with the Covid-19 outbreak, tropical countries have faced successive outbreaks of arboviruses, such as Dengue (DENV), Zika (ZIKV) and Chikungunya (CHIKV), presenting themselves as a challenge to the health systems of these countries. Arboviruses are diseases caused by viruses transmitted to humans through the bites of infected blood-sucking arthropods, predominantly *Aedes* mosquitoes [6], and their clinical manifestations can vary from mild and undifferentiated febrile disease to neurological, joint and hemorrhagic febrile syndromes [7]. In addition, it is observed that there is a low probability of predicting a possible outbreak [8], which may surprise health systems that, today, are saturated due to the Covid-19 pandemic.

The imminence of a syndemic state between Covid-19 and arboviruses (mainly Dengue) has been shown to be a concern of researchers from Latin American countries [9,10]. Even though it has not yet reported cases of co-infection, your treatment may be adversely affected, since the spectrum of drugs does not seem compatible [11]. Associated with this, researchers have reported a false positive diagnosis for Dengue in situations in which patients are affected by the SARS-CoV-2 virus [12,13], even though there was no genomic similarity between the viruses [14], which can make the diagnosis of these diseases even more difficult.

Brazil has historically faced cycles of arbovirus epidemics throughout its territory, with Dengue being the most prevalent arbovirus [15]. According to the most recent Brazilian epidemiological bulletin, until now (ie, April 06, 2020) approximately 500 thousand cases of arboviruses have been reported (DENV, ZIKV, CHIKV), 96% of which are associated with dengue, 2.73% Chikungunya and 0.33% to Zika [16], compared to 9506 cases of Covid-19 (until April 3) [17].

Thus, in order to optimize resources and care for patients, as well as to enable effective screening, allowing isolation and early management, biomarkers (obtained through blood counts at admission) can be effective in predicting the degree of severity of disease. Studies indicate that Covid-19 causes Lymphocytopenia [4] and Thrombocytopenia [18],

while arboviruses can cause Leukopenia, Lymphohistiocytosis and mild Lymphocytopenia [19–22].

Therefore, based on the clinical data of patients affected by Covid-19 or Arboviruses (DENV, ZIKV and CHIKV), this study aims to build a predictive model using machine learning algorithms, in order to screen and diagnose patients in case a possible syndemic state. It is also intended to share clinical data by the medical community about diseases of global circulation, in order to mitigate their impacts.

2 Materials and Methods

An electronic search was performed in the databases of Periódicos CAPES (portal of the Brazilian development agency CAPES, which aggregates numerous publishers of scientific journals), Google Scholar, Google Dataset and Science Direct, using the keywords, “Clinical features” OR “White blood cells count” OR “Haemogram” AND “coronavirus 2019” OR “COVID-19” OR “2019-nCoV” OR “SARS-CoV-2”. To search for clinical data related to arboviruses, the terms “Clinical features” OR “White blood cells count” OR “Haemogram” AND “Dengue” OR “Zika” OR “Chikungunya” were used. A Dataset containing clinical data from Brazilian patients Positive for SARS-CoV-2 was also added to the data set, made available by Hospital Israelita Albert Einstein [23].

The papers were chosen according to the criteria of: analysis of the abstract, title and body of the text, excluding works that presented only the average of the data obtained for a group of patients or that did not present the patients' blood count. Thus, 23 scientific papers were selected, all of which were written in English.

This study was carried out in accordance with the Declaration of Helsinki and in accordance with the terms of local legislation.

The predictive model was built using the open-source software Orange (v. 3.20.1) [24]. Before the implementation of the algorithm, the data were normalized (center by mean) and then submitted to the detection of outliers (abnormal data), using covariance assessment.

The input data for the training of the algorithm were the White Blood Cells count (WBC) and the Lymphocyte count, available in the articles, and the classes used for the prediction

were Covid-19 and Arboviruses. The type of algorithm used was SVM with Cost regression ($c = 1.50$, Kernel type RBF ($g = 1,04$) and the following optimization parameters: numerical tolerance = 0.005, without iteration limit.

The model was trained using the data and validated using the cross-validation methodology, with k -fold = 20. The validation method consists of dividing the data set into k parts, using $k-1$ parts for modeling (training) and the remaining part for testing. In this model the data set was tested twenty times, each one with a different fold from dataset.

The idea behind this type of algorithm is to map the data, transposing it into a high dimensional space in which hyperplanes separate the data into subgroups (clusters) according to their characteristics, allowing the classification problem to be more easily solved [25].

The model developed is available in supplementary materials.

3. Results and discussion

3.1 Characteristics of the included studies

The detailed characteristics of this study are found in the Dataset available as supplementary material. Data from 204 patients were used in total, and after detecting outliers, 120 patients remained positive for SARS-CoV-2 and 67 patients with arboviruses (DENV, ZIKV and CHIKV), in a wide age group and of both sexes, totaling 187 patients.

The parameters used for the evaluation and screening was the existence / prevalence of Leukopenia and Lymphohistiocytosis / Lymphocytopenia, based on what was previously reported in the literature. Tables 1 and 2 summarize the data found in the literature. It is worth noting that the dataset provided by Hospital Israelita Albert Einstein [23] was already normalized, and therefore it is not shown in the data set in the tables below.

Table 1. Clinical features of patients affected by Covid-19

Número de Pacientes	Disease	WBC ($10^9/L$)	Lymphocytes ($10^9/L$)	Observation	Reference
---------------------	---------	------------------	--------------------------	-------------	-----------

9	Covid-19	7.70 (5.07 -10.61)	1.18 (0.46-1.59)	Pregnant	[26]
5	Covid-19	7.6 (5.03 - 10.76)	0.74 (0.63 - 0.92)	Hemodialysis	[27]
5	Covid-19	8.75 (6.12 - 12,4)	1.42 (0.84-2.46)	Asymptomatic	[28]
5	Covid-19	5.68 (4.4 - 7.1)	1.56 (1.3- 1.7)	Reactivation	[29]
6	Covid-19	6.13 (4.3 – 11.4)	1.7 (0.6 – 2.7)	-	[30]
4	Covid-19	5.49 (4.23 – 6.84)	1.19 (0.42 - 1.98)	-	[31]
2	Covid-19	5.76 (4.37 - 7.16)	1.03 (0.88 – 1.19)	-	[32]
1	Covid-19	10.6	0.86	Pregnant	[33]
Total = 37		Mean = 7,06	Mean = 1,27		

96

97 Table 2. Clinical features of patients affected by arboviruses (DENV, ZIKV and CHIKV)

Número de Pacientes	Disease	WBC (10 ⁹ /L)	Lymphocytes (10 ⁹ /L)	Observation	Reference
1	Zika	2.28	0.83	Liver injury	[34]
1	Zika	6.10	1.0	-	[35]
1	Zika	4.90	1.42	-	[36]
12	Zika	5.96 (3.78 -10.13)	2.64 (0.39 – 7.09)	-	[37]
1	Zika	3.65	0.47	-	[38]
1	Zika	3.10	1.55	-	[39]
1	Chikungunya	3.10	0.7	-	[40]
14	Chikungunya	7.32 (3.00 -13.00)	3.44 (1.30 – 7.54)	Children	[41]
1	Chikungunya	15.7	6.09	-	[42]
1	Chikungunya	19.1	1.01	Erysipelas	[43]
3	Chikungunya	28.9 (21.8 -35.1)	1.2 (0.7- 1.2)	Fatal cases	[44]
1	Chikungunya	3.2	1.09	-	[45]
5	Zika/Dengue	3.65 (1.24 - 6.3)	0.96 (0.39 -1.84)	Coinfection	[46]
1	Dengue	1.60	0.93	-	[47]
40	Dengue	7.16 (4.43 - 11.9)	4.87 (1.90 - 6.70)	-	[48]
Total = 84		Média = 7,48	Média = 3,55		

98

99 3.2 Model assessment

100

		Predicted		
		Arboviruses	Covid -19	Σ
Actual	Arboviruses	82.1 %	6.9 %	63
	Covid -19	17.9 %	93.1 %	120
Σ		67	116	183

101

102 Figure 1. Confusion Matrix for classification test using an SVM machine learning algorithm

103

The results of a classification can be represented as a matrix called a confusion matrix, a square matrix (G x G) whose rows and columns represent the experimental and predicted data respectively [49].

The matrix shows that the model was able to predict more than 90% of Covid-19 cases and 82.1% of cases of arboviruses, based on clinical data obtained in the literature. The developed model also has an Area under Roc Curve (AUC) of 0.956, an accuracy of 0.891 and an precision of 0.893.

Lymphocytopenia is a clinical condition observed in patients with SARS-CoV-2, regardless of gender, age and / or pre-existence of comorbidities [50–52].

This condition allowed the correct classification of most of the observed cases. The classification error of individuals affected by arboviruses is also reported by Yan and collaborators, when describing two clinical pictures of SARS-Cov-2 as false positives for Dengue (DENV) [12] , showing the urgency in the development of more accurate methodologies.

Leukopenia presents to patients with arboviruses (DENV, ZIKV and CHIKV) in medium to intense degrees, according to the PAHO (Pan-American Health Organization) classification [53], and also presented in clinical studies [54,55]. Associated with this, some patients may experience lymphohistiocytosis [56–58]. These characteristics allowed the correct classification of 82.1% of the cases.

Cases misclassified totaling 10.93% of cases and are presented in Table 3:

Table 1. Misclassified cases

WBC (10 ⁹ /L)	Lymphocyte (10 ⁹ /L)	Actual	Predicted
5.6	2.2	Covid -19	Arboviruses
8.24	2.46	Covid -19	Arboviruses
6.48	1.98	Covid -19	Arboviruses
4.2	0.7	Covid -19	Arboviruses
4.23	1.28	Covid -19	Arboviruses
6.5	2.8	Covid -19	Arboviruses
11.4	2.7	Covid -19	Arboviruses

7.63	2.83	Covid -19	Arboviruses
4.4	1.08	Covid -19	Arboviruses
4.4	1.7	Covid -19	Arboviruses
4.3	1.2	Covid -19	Arboviruses
4.5	1.4	Covid -19	Arboviruses
7.56	2.12	Arboviruses	Covid -19
9.6	1.3	Arboviruses	Covid -19
7.54	1.66	Arboviruses	Covid -19
6.3	1.84	Arboviruses	Covid -19
6.1	1	Arboviruses	Covid -19
4.28	0.39	Arboviruses	Covid -19
5.86	1.76	Arboviruses	Covid -19
9.7	1.9	Arboviruses	Covid -19

126

127 From the analysis of table 3 and figure 2, we can find the factors that allow the erroneous
128 classification of patients: half of the patients affected by Covid-19 who have WBC values
129 ($\cong 5$) associated with low values of lymphocytes (> 2) are classified as having
130 arboviruses; while the other half is classified according to the high value of lymphocytes
131 Patients affected by arboviruses who have lymphocytopenia (lymphocytes ≤ 2) and
132 without leukopenia are classified as having Covid-19.

133

Figure 2. WBC x Lymphocyte count plot for patients classified incorrectly. The caption of each patient indicates the disease to which it is affected, the symbols indicate the predicted illness

4 Conclusion

The model developed was effective in discriminating based on clinical data between patients affected by Covid-19 and patients affected by arboviruses (DENV, ZIKV, CHIKV), being able to predict 93.1% of the cases of SARS-CoV-2 and 82.1% of cases of arboviruses. Even though it presented a not very satisfactory result for arboviruses, the model allows the screening of patients with Coronavirus (contagious), thus speeding up the isolation and hospitalization procedures.

Because it was developed using free software, this model can be used in public health systems in countries in the event of a simultaneous outbreak of arboviruses and Covid-19, minimizing the impacts of a possible collapse of the health system.

Acknowledgements

The author thanks the collaboration of doctors Marjorie Lobo and Tainá Cajazeira and the researcher Luane Barbosa for the review of this work.

References

- [1] C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Clinical features of patients infected with 2019 novel coronavirus in Wuhan , China, *Lancet*. (2020) 497–506. doi:10.1016/S0140-6736(20)30183-5.
- [2] World Health Organization, Coronavirus disease 2019 (COVID-19) Situation Report – 76, 2019 (2020). https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200405-sitrep-76-covid-19.pdf?sfvrsn=6ecf0977_4.
- [3] E. Dong, H. Du, L. Gardner, An interactive web-based dashboard to track COVID-19 in real time, *Lancet Infect. Dis.* 3099 (2020) 19–20. doi:10.1016/S1473-3099(20)30120-1.
- [4] W. Guan, Z. Ni, Y. Hu, W. Liang, C. Ou, J. He, L. Liu, H. Shan, C. Lei, D.S.C. Hui, B. Du, L. Li, G. Zeng, K. Yuen, R. Chen, C. Tang, T. Wang, P. Chen, J. Xiang, S. Li, J. Wang, Z. Liang, Y. Peng, L. Wei, Y. Liu, Y. Hu, P. Peng, J. Wang, J. Liu, Z. Chen, G. Li, Z. Zheng, S. Qiu, J. Luo, C. Ye, S. Zhu, Clinical Characteristics of Coronavirus Disease 2019 in China, *N. Engl. J. Med.* (2020) 1–13. doi:10.1056/NEJMoa2002032.
- [5] F. Zhou, T. Yu, R. Du, G. Fan, Y. Liu, Z. Liu, J. Xiang, Y. Wang, B. Song, X. Gu, L. Guan, Y. Wei, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan , China : a retrospective cohort study, *Lancet*. 395 (2020) 1054–1062. doi:10.1016/S0140-6736(20)30566-3.
- [6] A. Wilder-smith, D.J. Gubler, S.C. Weaver, T.P. Monath, D.L. Heymann, T.W. Scott, Epidemic arboviral diseases : priorities for research and public health, *Lancet Infect. Dis.* 3099 (2016) 1–6. doi:10.1016/S1473-3099(16)30518-7.

- 180 [7] A.P.B. Von Zuben, Maria Rita Donalisio, André Ricardo Ribas Freitas,
181 Arboviroses emergentes no Brasil : desafios para a clínica e implicações para a
182 saúde pública, Rev. Saude Publica. 51 (2017) 10–15.
- 183 [8] D. Musso, A.J. Rodriguez-morales, J.E. Levi, D.J. Gubler, Personal View
184 Unexpected outbreaks of arbovirus infections : lessons learned from the Pacific
185 and tropical America, Lancet Infect. Dis. 3099 (2018) 1–7. doi:10.1016/S1473-
186 3099(18)30269-X.
- 187 [9] A.J. Rodriguez-Morales, V. Gallego, J.P. Escalera-Antezana, C.A. Méndez, L.I.
188 Zambrano, C. Franco-Paredes, J.A. Suárez, H.D. Rodriguez-Enciso, G.J. Balbin-
189 Ramon, E. Savio-Larriera, A. Risquez, S. Cimerman, COVID-19 in Latin
190 America: The implications of the first confirmed case in Brazil, Travel Med.
191 Infect. Dis. (2020) 101613. doi:10.1016/j.tmaid.2020.101613.
- 192 [10] M. Saavedra-Velasco, C. Chiara-Chilet, R. Pichardo-Rodriguez, A. Grandez-
193 Urbina, F. Inga-Berrosipi, Coinfección entre dengue y COVID-19: Necesidad de
194 abordaje en zonas endémicas, Rev. Fac. Cienc. Med. Cordoba. 77 (2020) 52–54.
195 doi:10.31053/1853.0605.v77.n1.28031.
- 196 [11] J. Navarro, J. Arrivillaga-henríquez, J. Salazar-loor, A.J. Rodriguez-morales,
197 COVID-19 and dengue, co-epidemics in Ecuador and other countries in Latin
198 America: Pushing strained health care systems over the edge, Travel Med. Infect.
199 Dis. (2020) 101656. doi:10.1016/j.tmaid.2020.101656.
- 200 [12] G. Yan, C.K. Lee, L.T.M. Lam, B. Yan, Y.X. Chua, A.Y.N. Lim, K.F. Phang, G.
201 Sen Kew, H. Teng, C.H. Ngai, L. Lin, R.M. Foo, S. Pada, L.C. Ng, P.A.
202 Tambyah, Covert COVID-19 and false-positive dengue serology in Singapore,
203 Lancet Infect. Dis. 3099 (2020) 30158. doi:10.1016/S1473-3099(20)30158-4.
- 204 [13] B. joob, V. Wiwanitkit, COVID-19 can present with a rash and be mistaken for
205 Dengue, J. Am. Acad. Dermatol. (2020) 19–22. doi:10.1016/j.jaad.2020.03.036.
- 206 [14] Y. Li, B. Liu, J. Cui, Z. Wang, Y. Shen, Y. Xu, K. Yao, Y. Guan, Similarities and
207 Evolutionary Relationships of COVID-19 and Related Viruses, (2020).
208 <http://arxiv.org/abs/2003.05580>.
- 209 [15] V.I. Avelino-Silva, J.F. Ramos, Arboviroses e políticas públicas no Brasil
210 Arboviruses and public policies in Brazil, Rev. Ciências Em Saúde. 7 (2017) 1–2.

- 211 doi:10.21876/rcsfmit.v7i3.675.
- 212 [16] Brasil, Monitoramento dos casos de arboviroses urbanas transmitidas pelo Aedes
213 Aegypti (dengue, chikungunya e zika), Semanas Epidemiológicas 1 a 13, 2020,
214 Bol. Epidemiológico 14. 51 (2020) 1–34.
215 [https://www.saude.gov.br/images/pdf/2020/April/03/Boletim-epidemiologico-](https://www.saude.gov.br/images/pdf/2020/April/03/Boletim-epidemiologico-SVS-14.pdf)
216 SVS-14.pdf.
- 217 [17] Brasil, Doença pelo Coronavírus 2019, Bol. Epidemiológico Do Cent. Operações
218 Emergência Em Saúde Pública 06. 06 (2020) 1–23.
219 [https://portalarquivos.saude.gov.br/images/pdf/2020/April/03/BE6-Boletim-](https://portalarquivos.saude.gov.br/images/pdf/2020/April/03/BE6-Boletim-Especial-do-COE.pdf)
220 Especial-do-COE.pdf.
- 221 [18] G. Lippi, M. Plebani, B. Michael, Thrombocytopenia is associated with severe
222 coronavirus disease 2019 (COVID-19) infections : A meta -analysis, Clin.
223 Chim. Acta. 506 (2020) 145–148. doi:10.1016/j.cca.2020.03.022.
- 224 [19] T. Elias, C. Fernanda, A. Francesli, N. Reis, N. Santos, M. Lima, E. Márcia, S.
225 Cabrera, I. Nuremberg, F. Rodrigues, L. Elisa, A. Antônio, Clinical , laboratory
226 and virological data from suspected ZIKV patients in an endemic arbovirus area,
227 J. Clin. Virol. 96 (2017) 20–25. doi:10.1016/j.jcv.2017.09.002.
- 228 [20] M. Kapdi, I.R.A. Shah, Dengue and haemophagocytic lymphohistiocytosis,
229 Scand. J. Infect. Dis. (2012) 708–709. doi:10.3109/00365548.2011.652667.
- 230 [21] S.-C.J. Wæhre T, Maagard A, Tappe D, Cadar D, Zika Virus Infection after
231 Travel to Tahiti , December 2013, Emerg. Infect. Dis. 20 (2014) 8–10.
- 232 [22] L. Dupuis-Maguiraga, M. Noret, S. Brun, R. Le Grand, G. Gras, P. Roques,
233 Chikungunya Disease : Infection-Associated Markers from the Acute to the
234 Chronic Phase of Arbovirus-Induced Arthralgia, PLoS Negl. Trop. Dis. 6 (2012).
235 doi:10.1371/journal.pntd.0001446.
- 236 [23] E. Data4u, Diagnosis of COVID-19 and its clinical spectrum, Kaggle. (2020).
237 <https://www.kaggle.com/einsteindata4u/covid19> (accessed April 5, 2020).
- 238 [24] J. Demsar, B. Zupan, G. Leban, T. Curk, Orange : From Experimental Machine
239 Learning, Knowl. Discov. Databases PKDD 2004. (2004) 537–539.
240 doi:10.1007/978-3-540-30116-5_58.

- 241 [25] J. Luts, F. Ojeda, R. Van de Plas Raf, B. De Moor, S. Van Huffel, J.A.K.
242 Suykens, A tutorial on support vector machine-based methods for classification
243 problems in chemometrics, *Anal. Chim. Acta.* 665 (2010) 129–145.
244 doi:10.1016/j.aca.2010.03.030.
- 245 [26] H. Chen, J. Guo, C. Wang, F. Luo, X. Yu, W. Zhang, J. Li, D. Zhao, D. Xu, Q.
246 Gong, J. Liao, H. Yang, W. Hou, Y. Zhang, Clinical characteristics and
247 intrauterine vertical transmission potential of COVID-19 infection in nine
248 pregnant women: a retrospective review of medical records, *Lancet.* 395 (2020)
249 809–815. doi:10.1016/S0140-6736(20)30360-3.
- 250 [27] R. Wang, C. Liao, H. He, C. Hu, Z. Wei, Z. Hong, C. Zhang, M. Liao, H. Shui,
251 COVID-19 in Hemodialysis Patients: A Report of 5 Cases, *Am. J. Kidney Dis.*
252 (2020). doi:10.1053/j.ajkd.2020.03.009.
- 253 [28] F. Ye, S. Xu, Z. Rong, R. Xu, X. Liu, P. Deng, H. Liu, X. Xu, Delivery of
254 infection from asymptomatic carriers of COVID-19 in a familial cluster, *Int. J.*
255 *Infect. Dis.* 105 (2020) 72–80. doi:10.1016/j.ijid.2020.03.042.
- 256 [29] G. Ye, Z. Pan, Y. Pan, Q. Deng, L. Chen, J. Li, Y. Li, X. Wang, Clinical
257 characteristics of severe acute respiratory syndrome coronavirus 2 reactivation, *J.*
258 *Infect.* (2020) 3–6. doi:10.1016/j.jinf.2020.03.001.
- 259 [30] J.F.W. Chan, S. Yuan, K.H. Kok, K.K.W. To, H. Chu, J. Yang, F. Xing, J. Liu,
260 C.C.Y. Yip, R.W.S. Poon, H.W. Tsoi, S.K.F. Lo, K.H. Chan, V.K.M. Poon,
261 W.M. Chan, J.D. Ip, J.P. Cai, V.C.C. Cheng, H. Chen, C.K.M. Hui, K.Y. Yuen,
262 A familial cluster of pneumonia associated with the 2019 novel coronavirus
263 indicating person-to-person transmission: a study of a family cluster, *Lancet.* 395
264 (2020) 514–523. doi:10.1016/S0140-6736(20)30154-9.
- 265 [31] Z. Wang, X. Chen, Y. Lu, F. Chen, W. Zhang, Clinical characteristics and
266 therapeutic procedure for four cases with 2019 novel coronavirus pneumonia
267 receiving combined Chinese and Western medicine treatment, *Biosci. Trends.* 14
268 (2020) 64–68. doi:10.5582/bst.2020.01030.
- 269 [32] P. Yu, J. Zhu, Z. Zhang, Y. Han, L. Huang, A familial cluster of infection
270 associated with the 2019 novel coronavirus indicating potential person-to-person
271 transmission during the incubation period, *J. Infect. Dis.* (2020) 1–5.

- 272 doi:10.1093/infdis/jiaa077.
- 273 [33] X. Wang, Z. Zhou, J. Zhang, F. Zhu, Y. Tang, X. Shen, A case of 2019 Novel
274 Coronavirus in a pregnant woman with preterm delivery, Clin. Infect. Dis.
275 (2020). doi:10.1093/cid/ciaa200.
- 276 [34] Y. Wu, X. Cui, N. Wu, R. Song, W. Yang, W. Zhang, D. Fan, Z. Chen, J. An, A
277 unique case of human Zika virus infection in association with severe liver injury
278 and coagulation disorders, Sci. Rep. 7 (2017) 1–8. doi:10.1038/s41598-017-
279 11568-4.
- 280 [35] G.H.Y. Leung, R.W. Baird, J. Druce, N.M. Anstey, Zika virus infection in
281 Australia following a monkey bite in Indonesia, Southeast Asian J. Trop. Med.
282 Public Health. 46 (2015) 460–464.
- 283 [36] H.C. Jang, W.B. Park, U.J. Kim, J.Y. Chun, S.J. Choi, P.G. Choe, S.I. Jung, Y.
284 Jee, N.J. Kim, E.H. Choi, M.D. Oh, First imported case of Zika virus infection
285 into Korea, J. Korean Med. Sci. 31 (2016) 1173–1177.
286 doi:10.3346/jkms.2016.31.7.1173.
- 287 [37] J. Li, C.Y. Chong, N.W. Tan, C.F. Yung, N.W. Tee, K.C. Thoon, Characteristics
288 of Zika Virus Disease in Children: Clinical, Hematological, and Virological
289 Findings from an Outbreak in Singapore, Clin. Infect. Dis. 64 (2017) 1445–1448.
290 doi:10.1093/cid/cix137.
- 291 [38] L.H. Chen, Zika Virus Infection in a Massachusetts Resident After Travel to
292 Costa Rica: A Case Report, Ann. Intern. Med. 164 (2016) 574. doi:10.7326/L16-
293 0075.
- 294 [39] A.F. Cardona-Cardona, A.J. Rodríguez Morales, Severe abdominal pain in a
295 patient with Zika infection: A case in Risaralda, Colombia, J. Infect. Public
296 Health. 9 (2016) 372–373. doi:10.1016/j.jiph.2016.03.001.
- 297 [40] C. Therrien, G. Jourdan, K. Holloway, C. Tremblay, M.A. Drebot, First Imported
298 Case of Chikungunya Virus Infection in a Travelling Canadian Returning from
299 the Caribbean, Can. J. Infect. Dis. Med. Microbiol. 2016 (2016).
300 doi:10.1155/2016/2980297.
- 301 [41] G.M. Oliveira, T.M.A. Marques, J.R. Dos Santos, E.D.F. Daher, R.D. Leite, E.S.

- 302 Girão, R. da J.P. Neto, Clinical and laboratory profiles of children with sever
303 chikungunya infection, Rev. Soc. Bras. Med. Trop. 52 (2019) 2017–2020.
304 doi:10.1590/0037-8682-0232-2018.
- 305 [42] M.M. Aly, S. Ali, A.F. Muianga, V. Monteiro, J.G. Gallego, J. Weyer, K.I. Falk,
306 J.T. Paweska, J. Cliff, E.S. Gudo, Severe Chikungunya infection in Northern
307 Mozambique: a case report, BMC Res. Notes. 10 (2017) 4–9.
308 doi:10.1186/s13104-017-2417-z.
- 309 [43] M.C. Schechter, K.A. Workowski, J.K. Fairley, Unusual Presentation of
310 Chikungunya Virus Infection With Concomitant Erysipelas in a Returning
311 Traveler From the Caribbean: A Case Report, Open Forum Infect. Dis. 1 (2014)
312 ofu097–ofu097. doi:10.1093/ofid/ofu097.
- 313 [44] J.M. de la Hoz, B. Bayona, S. Vilorio, J.L. Accini, H.S. Juan-Vergara, D. Viasus,
314 Fatal cases of Chikungunya virus infection in Colombia: Diagnostic and
315 treatment challenges, J. Clin. Virol. 69 (2015) 27–29.
316 doi:10.1016/j.jcv.2015.05.021.
- 317 [45] I. Eckerle, V.T. Briciu, Ergönül, M. Lupş, A. Papa, A. Radulescu, S. Tsiodras,
318 C. Tsitou, C. Drosten, V.R. Nussenblatt, C.B. Reusken, L.A. Sigfrid, N.J.
319 Beeching, Emerging souvenirs—clinical presentation of the returning traveller
320 with imported arbovirus infections in Europe, Clin. Microbiol. Infect. 24 (2018)
321 240–245. doi:10.1016/j.cmi.2018.01.007.
- 322 [46] P.Y. Chia, H. Sen Yew, H. Ho, A. Chow, S.P. Sadarangani, M. Chan, Y.W. Kam,
323 C.Y. Chong, K.C. Thoon, C.F. Yung, J.H. Li, D.C. Lye, P.P. De, L.F.P. Ng, T.W.
324 Yeo, Y.S. Leo, Clinical features of patients with Zika and dengue virus co-
325 infection in Singapore, J. Infect. 74 (2017) 611–615.
326 doi:10.1016/j.jinf.2017.03.007.
- 327 [47] M. Mardani, F. Abbasi, M. Aghahasani, B. Ghavam, First Iranian imported case
328 of dengue, Int. J. Prev. Med. 4 (2013) 1075–1077.
- 329 [48] S. Advani, S. Agarwal, J. Verma, Haemogram profile of dengue fever in adults
330 during 19 September – 12 November 2008: A study of 40 cases from Delhi.,
331 Dengue Bull. 35 (2011) 71–75. <https://apps.who.int/iris/handle/10665/171014>.
- 332 [49] D. Ballabio, F. Grisoni, R. Todeschini, Multivariate comparison of classification

- 333 performance measures, *Chemom. Intell. Lab. Syst.* 174 (2018) 33–44.
 334 doi:10.1016/j.chemolab.2017.12.004.
- 335 [50] L. Zeng, S. Xia, W. Yuan, K. Yan, F. Xiao, J. Shao, W. Zhou, Neonatal Early-
 336 Onset Infection with SARS-CoV-2 in 33 Neonates Born to Mothers with
 337 COVID-19 in Wuhan, China, *JAMA Pediatr.* 23 (2020) 4–6.
 338 doi:10.1001/jamapediatrics.2020.0878.
- 339 [51] X. Yang, Y. Yu, J. Xu, H. Shu, J. Xia, H. Liu, Y. Wu, L. Zhang, Z. Yu, M. Fang,
 340 T. Yu, Y. Wang, S. Pan, X. Zou, S. Yuan, Y. Shang, Clinical course and
 341 outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan,
 342 China: a single-centered, retrospective, observational study, *Lancet Respir. Med.*
 343 2600 (2020) 1–7. doi:10.1016/S2213-2600(20)30079-5.
- 344 [52] D. Wu, T. Wu, Q. Liu, Z. Yang, The SARS-CoV-2 outbreak: what we know., *Int.*
 345 *J. Infect. Dis.* (2020). doi:10.1016/j.ijid.2020.03.004.
- 346 [53] Pan American Health Organization (PAHO), Tool for the diagnosis and care of
 347 patients with suspected arboviral diseases, 2017.
 348 <http://iris.paho.org/xmlui/handle/123456789/33895>.
- 349 [54] E.L. Azeredo, F.B. dos Santos, L.S. Barbosa, T.M.A. Souza, J. Badolato-Corrêa,
 350 J.C. Sánchez-Arcila, P.C.G. Nunes, L.M. de-Oliveira-Pinto, A.M. de Filippis, M.
 351 Dal Fabbro, I. Hoscher Romanholi, R. Cunha, Clinical and Laboratory Profile of
 352 Zika and Dengue Infected Patients: Lessons Learned From the Co-circulation of
 353 Dengue, Zika and Chikungunya in Brazil, *PLoS Curr.* (2018) 1–20.
 354 doi:10.1371/currents.outbreaks.0bf6aeb4d30824de63c4d5d745b217f5.
- 355 [55] R. Li, J. Ding, G. Ding, X. Fan, Y. He, X. Wang, H. Zhang, J. Ji, H. Li, Zika
 356 virus infections, a review, *Radiol. Infect. Dis.* 4 (2017) 88–93.
 357 doi:10.1016/j.jrid.2017.01.002.
- 358 [56] S.L. Beltrán-Silva, S.S. Chacón-Hernández, E. Moreno-Palacios, J.Á. Pereyra-
 359 Molina, Clinical and differential diagnosis: Dengue, chikungunya and Zika, *Rev.*
 360 *Médica Del Hosp. Gen. México.* 81 (2018) 146–153.
 361 doi:10.1016/j.hgmx.2016.09.011.
- 362 [57] E.M. Ellis, T.M. Sharp, J. Pérez-Padilla, L. González, B.K. Poole-Smith, E.
 363 Lebo, C. Baker, M.J. Delorey, B. Torres-Velasquez, E. Ochoa, B. Rivera-Garcia,

- 364 H. Díaz-Pinto, L. Clavell, A. Puig-Ramos, G.E. Janka, K.M. Tomashek,
 365 Incidence and Risk Factors for Developing Dengue-Associated Hemophagocytic
 366 Lymphohistiocytosis in Puerto Rico, 2008 - 2013, PLoS Negl. Trop. Dis. 10
 367 (2016) 2008–2013. doi:10.1371/journal.pntd.0004939.
- 368 [58] T.M. Sharp, L. Gaul, A. Muehlenbachs, E. Hunsperger, J. Bhatnagar, R.
 369 Lueptow, G.A. Santiago, J.L. Muñoz-Jordan, D.M. Blau, P. Ettestad, J.D. Bissett,
 370 S.C. Ledet, S.R. Zaki, K.M. Tomashek, Fatal hemophagocytic
 371 lymphohistiocytosis associated with locally acquired dengue virus infection -
 372 New Mexico and Texas, 2012, Morb. Mortal. Wkly. Rep. 63 (2014) 49–54.
 373 doi:10.1016/j.annemergmed.2014.04.007.
- 374
- 375